Jan 29, 2020
Anat Cohen-Dayag PhD chief executive officer, Compugen discusses the current immune-oncology treatment landscape, with only 20-30% of patients responding to currently available treatments, and the missing link that she believes her company may have found to improve the success rate. Anat talks about how Compugen's computational discovery platform works to discover new drug targets for treating solid tumors and how lead candidate COM701 has shown encouraging early stage results to date.
#immuno-oncology #cancer. #colorectalcancer